AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15144469
Drug: Symptomatic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic drugs only (Control)
Trial: 29504780
Drug: Reduced nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced nicotine content (RNC) cigarettes (0.4 mg/g to 15.8 mg/g nicotine)
Trial: 29504780
Drug: Reduced nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced nicotine content (RNC) cigarettes (0.4 mg/g)
Trial: 27475338
Drug: Intravenous vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous vitamin B6 (60 mg of intravenous pyridoxal 5'-phosphate after each thrice-weekly hemodialysis session)
Trial: 15370183
Drug: Individualized homeopathy
RxNorm normalized name: Urtica urens homeopathic preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized homeopathy treatment
Trial: 15370183
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (continued)
Trial: 15370183
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (switched to placebo)
Trial: 8087784
Drug: Standard doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard doses of chemotherapy
Trial: 3195529
Drug: Antibiotics plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics plus 5 mL/kg/d for four days of IgM-enriched immunoglobulin intravenously
Trial: 6897618
Drug: Bromhexin tablets
RxNorm normalized name: bromhexine
DrugBank: Bromhexine (DB09019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromhexin tablets 8 mg
Trial: 6897618
Drug: Bisolvon tablets
RxNorm normalized name: Bisolvon metabolite vIII
DrugBank: Ambroxol (DB06742)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisolvon tablets 8 mg
Trial: 6897618
Drug: Bromhexine (overall
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromhexine (overall pharmacokinetics)
Trial: 29160099
Drug: rAAV1-CMV-hGAA gene
RxNorm normalized name: CMV-immune globulin
DrugBank: Human cytomegalovirus immune globulin (DB13886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rAAV1-CMV-hGAA gene therapy
Trial: 17561982
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy (HRT) in Turner syndrome
Trial: 17561982
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives in controls
Trial: 9822044
Drug: Long-term treatment
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term treatment protocol (LTP) with PGE1: 2-hour infusions (60 microg PGE1, 5 days each week for 4 weeks), followed by twice a week for 4 weeks, then monitoring for 3 months.
Trial: 9822044
Drug: Short-term treatment
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term treatment protocol (STP) with PGE1: 2-hour infusion over 2 days (1st day: morning 20 microg, afternoon 40 microg; 2nd day: morning and afternoon 60 microg), followed by full dosage for subsequent cycles.
Trial: 2644595
Drug: Clotrimazole 500
RxNorm normalized name: clotrimazole 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clotrimazole 500 mg vaginal suppositories, administered once weekly for 2 weeks
Trial: 2644595
Drug: Clotrimazole 500
RxNorm normalized name: clotrimazole 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clotrimazole 500 mg vaginal tablets, administered once a month during prophylactic phase
Trial: 2644595
Drug: Placebo, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered once a month during prophylactic phase
Trial: 30016185
Drug: LVHL2 (low-velocity,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LVHL2 (low-velocity, high-load, twice-weekly)
Trial: 30016185
Drug: LVHL1 (low-velocity,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LVHL1 (low-velocity, high-load, once-weekly)
Trial: 30016185
Drug: HVLL2 (high-velocity,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HVLL2 (high-velocity, low-load, twice-weekly)
Trial: 28151904
Drug: Ultrasound-guided interfascial
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided interfascial block (IFB) with 10 mL of 0.6% lidocaine
Trial: 25995169
Drug: Icotinib administered
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Icotinib administered with food
Trial: 25995169
Drug: Icotinib administered
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Icotinib administered without food
Trial: 25995169
Drug: Icotinib pharmacokinetics
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Icotinib pharmacokinetics model
Trial: 23956164
Drug: Iron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplementation (3 mg/kg/day of elemental iron and multivitamins)
Trial: 19528561
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate (elemental calcium, 1500 mg/d)
Trial: 15383014
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of elemental iron per day
Trial: 15383014
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of elemental iron per day
Trial: 15383014
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg of elemental iron (placebo)
Trial: 11465525
Drug: Granisetron (1-1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron (1-1.5 mg)
Trial: 9682398
Drug: cell culture-derived
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cell culture-derived vaccine
Trial: 9682398
Drug: egg-derived vaccine
RxNorm normalized name: EGG
DrugBank: Egg (DB10529)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: egg-derived vaccine
Trial: 3410479
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal (20 g)
Trial: 17916665
Drug: Amlodipine 5-10
RxNorm normalized name: amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5-10 mg with perindopril 4-8 mg added as needed
Trial: 17916665
Drug: Atenolol 50-100
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 50-100 mg with bendroflumethiazide 1.25-2.5 mg and potassium added as needed
Trial: 16433964
Drug: Milk containing
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk containing 2.0 g CPP-ACP/l
Trial: 16433964
Drug: Milk containing
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk containing 5.0 g CPP-ACP/l
Trial: 14657887
Drug: Peanut skin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peanut skin prick tests (SPTs) and oral peanut challenges for groups 2 and 4 with positive SPT responses; peanut-specific IgE measurement for groups 2 and 4 with IgE levels < 15 kU/L.
Trial: 9099448
Drug: Flunarizine 30
RxNorm normalized name: flunarizine
DrugBank: Flunarizine (DB04841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunarizine 30 mg oral dose
Trial: 3096723
Drug: Methohexitone 1.5-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methohexitone 1.5-2 mg kg‐1
Trial: 29316946
Drug: Combined cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined cognitive behavioural group psychotherapy and physiotherapy (9 weekly sessions with a 4-week break between modules)
Trial: 12666731
Drug: 1% lindane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% lindane shampoo and oral trimethoprim/sulfamethoxazole (group 2)
Trial: 10547175
Drug: Antidepressants (sertraline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants (sertraline hydrochloride)
Trial: 10547175
Drug: Combined exercise
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined exercise and medication
Trial: 8683243
Drug: Amifostine (910
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amifostine (910 mg/m2)
Trial: 1805048
Drug: Imipenem/cilastatine (IPM/CS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem/cilastatine (IPM/CS) 1 g twice daily
Trial: 1805048
Drug: Latamoxef (LMOX)
RxNorm normalized name: latamoxef
DrugBank: Latamoxef (DB04570)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Latamoxef (LMOX) 2 g plus Tobramycin (TOB) 90 mg twice daily
Trial: 6402917
Drug: Oral tegafur
RxNorm normalized name: tegafur
DrugBank: Tegafur (DB09256)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Oral tegafur (1 gm/m2/days 1‐21)
Trial: 6402917
Drug: 5-fluorouracil (5-Fu,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fluorouracil (5-Fu, 500 mg/m2/days 1‐4, then 250 mg/m2 on days 6, 8, 10, 12)
Trial: 6402917
Drug: Oral tegafur
RxNorm normalized name: tegafur
DrugBank: Tegafur (DB09256)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Oral tegafur
Trial: 29105958
Drug: Nebivolol/valsartan SPC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol/valsartan SPC (5 mg/80 mg)
Trial: 29105958
Drug: Nebivolol/valsartan SPC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol/valsartan SPC (5 mg/160 mg)
Trial: 29105958
Drug: Nebivolol/valsartan SPC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol/valsartan SPC (10 mg/160 mg)
Trial: 29105958
Drug: Nebivolol/valsartan SPC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol/valsartan SPC (10 mg/320 mg)
Trial: 29105958
Drug: Comparator weighted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator weighted average (non-β-blocker/renin-angiotensin-aldosterone system inhibitor SPCs)
Trial: 17272996
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose interferon-alpha (3 MU three times per week for 12 months)
Trial: 17272996
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose interferon-alpha (5 MU three times per week for 6 months)
Trial: 16095546
Drug: Water-based exercise
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Water-based exercise treatment
Trial: 2188928
Drug: Mitoxantrone 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitoxantrone 12 mg/m2 i.v. every three weeks
Trial: 483111
Drug: 20% mannitol-bisacodyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% mannitol-bisacodyl solution for oral use
Trial: 31321771
Drug: Intravenous pantoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous pantoprazole 40 mg once daily
Trial: 28624340
Drug: Teriparatide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teriparatide (20 µg daily)
Trial: 11728945
Drug: Selective COX‐2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective COX‐2 inhibitors
Trial: 24620015
Drug: Nonselective COX‐2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonselective COX‐2 inhibitors
Trial: 12066422
Drug: Interpretation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interpretation of target symbols (e.g., interpreting '>' as a right-pointing arrow or as a headlight shining to the left)
Trial: 9800669
Drug: hMG/hCG therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hMG/hCG therapy
Trial: 2515625
Drug: Praziquantel (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praziquantel (40 mg/kg), 10 weeks after treatment
Trial: 2515625
Drug: Praziquantel (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praziquantel (40 mg/kg), 6 weeks after treatment
Trial: 2515625
Drug: Praziquantel (double
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praziquantel (double dose of 40 mg/kg), within 10 days after treatment
Trial: 78718
Drug: Triprolidine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triprolidine (2.5 mg)
Trial: 28606735
Drug: Prednisolone 5
RxNorm normalized name: prednisolone 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 5 mg twice daily
Trial: 28606735
Drug: Dexamethasone 0.5
RxNorm normalized name: dexamethasone 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 0.5 mg daily
Trial: 19729401
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group with treatment intensification
Trial: 19729401
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with treatment intensification
Trial: 19729401
Drug: Both study
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both study groups with proper treatment intensification
Trial: 17250690
Drug: Anti-oxidant supplement
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-oxidant supplement (beta-carotene 9 mg/day, vitamin C 1500 mg/day, vitamin E 130 mg/day, zinc 45 mg/day, selenium 76 microg/day, garlic 150 mg/day)
Trial: 9754182
Drug: Topical cyclosporin
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cyclosporin A (CsA) 2% in maize oil
Trial: 29317666
Drug: Rituximab 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab 0.1 mg/m2
Trial: 29317666
Drug: Rituximab 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab 0.3 mg/m2
Trial: 29317666
Drug: Proposed biosimilar
RxNorm normalized name: Propoven
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Proposed biosimilar 0.3 mg/m2
Trial: 29317666
Drug: Reference product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference product 0.3 mg/m2
Trial: 29317666
Drug: Rituximab 1
RxNorm normalized name: rituximab 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab 1 mg/m2
Trial: 28424854
Drug: Narrative Enhancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrative Enhancement and Cognitive Therapy (NECT) as an add-on to treatment as usual
Trial: 19299763
Drug: Preoperative BNP
RxNorm normalized name: BNP
DrugBank: Nesiritide (DB04899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative BNP elevation > or =50 pg/mL
Trial: 19299763
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of preoperative BNP elevation > or =50 pg/mL and postoperative cTn I elevation > or =2 ng/mL
Trial: 11166379
Drug: Therapies aimed
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapies aimed at inhibiting lymphoid cell apoptosis
Trial: 11166379
Drug: Anti-cytokine and
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-cytokine and anti-inflammatory therapies
Trial: 8573926
Drug: Moist toilet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moist toilet paper preparation
Trial: 8573926
Drug: Recycled toilet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recycled toilet paper preparation
Trial: 8573926
Drug: Conventional toilet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional toilet paper preparation
Trial: 2561015
Drug: Naltrexone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (50 mg per os)
Trial: 25452062
Drug: Cessation group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cessation group therapy
Trial: 21692408
Drug: Propofol 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 0.5 mg/kg + Dexamethasone 4 mg
Trial: 21692408
Drug: Propofol 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 0.5 mg/kg + Dexamethasone 8 mg
Trial: 19491220
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human GH (2 mg/d sc; n = 22)
Trial: 17326082
Drug: Double-dose (D(D))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-dose (D(D)) Gd-DTPA
Trial: 17326082
Drug: Single-dose (D(S))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose (D(S)) Gd-DTPA
Trial: 15075538
Drug: IL-2 immunotherapy
RxNorm normalized name: Ile
DrugBank: Isoleucine (DB00167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IL-2 immunotherapy with HAART
Trial: 7919965
Drug: Immunotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy with IFN-alpha and IL-2
Trial: 7919965
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (surgery or chemotherapy)
Trial: 3290263
Drug: Amiloride 5
RxNorm normalized name: amiloride 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiloride 5 mg twice a day
Trial: 30171747
Drug: High-dose metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose metformin monotherapy (HMET) 1,500 mg
Trial: 30171747
Drug: Low-dose metformin/linagliptin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose metformin/linagliptin combination therapy (LMET + DPP4) 750 mg metformin + 5 mg linagliptin
Trial: 21712672
Drug: Low-dose low-molecular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose low-molecular weight heparin (LMWH)
Trial: 19291301
Drug: Fixed-dose AS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose AS (25 mg)/AQ (67.5 mg)
Trial: 19291301
Drug: Loose AS
RxNorm normalized name: loose wheat smut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loose AS (50 mg) + AQ (153 mg)
Trial: 19291301
Drug: Fixed-dose AS/AQ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose AS/AQ
Trial: 17355631
Drug: Ganciclovir treatment
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ganciclovir treatment for 21 days
Trial: 9689189
Drug: Ipriflavone, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipriflavone, 200 mg three times daily
Trial: 8279371
Drug: Alteplase (rt-PA)
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alteplase (rt-PA) 100 mg/3 hours (adjusted for body weight < 65 kg)
Trial: 8279371
Drug: Heparin (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (dose adjusted to maintain therapeutic partial thromboplastin time)
Trial: 2638321
Drug: Glycine-fortified ORS
RxNorm normalized name: Glycine
DrugBank: Glycine (DB00145)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glycine-fortified ORS at a concentration of 111 mmol/L (8.4 g/L)
Trial: 30742834
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg MB‐MMX
Trial: 24673054
Drug: Loratadine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loratadine (10 mg, once a day)
Trial: 22764339
Drug: Two‐wave MLS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two‐wave MLS laser irradiation (dose 6.6 J/point)
Trial: 22764339
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (simulated laser therapy without actual irradiation)
Trial: 11849576
Drug: Ropivacaine 1
RxNorm normalized name: ROPivacaine 1% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 1 mg x ml(-1)
Trial: 11849576
Drug: Ropivacaine 2
RxNorm normalized name: fentanyl-ropivacaine 2 mcg/mL-0.1% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 2 mg x ml(-1)
Trial: 11849576
Drug: Ropivacaine 3
RxNorm normalized name: fentanyl-ropivacaine 3 mcg/mL-0.1%-0.9% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 3 mg x ml(-1)
Trial: 28179255
Drug: Placebo (PL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PL) + l-NAME
Trial: 28179255
Drug: Losartan (LOS)
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Losartan (LOS) + l-NAME
Trial: 28179255
Drug: Manidipine (MANI)
RxNorm normalized name: manidipine
DrugBank: Manidipine (DB09238)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manidipine (MANI) + l-NAME
Trial: 23919898
Drug: Olanzapine (10-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (10-40 mg/day)
Trial: 14735129
Drug: High-dose (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose (2.5 x seizure threshold) bilateral (BL) ECT
Trial: 14735129
Drug: High-dose (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose (6 x seizure threshold) RUL ECT
Trial: 14735129
Drug: RUL ECT
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RUL ECT (all doses)
Trial: 11179154
Drug: Educational intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Educational intervention with two individual treatment sessions and two telephone follow up calls, supported by a comprehensive educational pack.